Ready to play
Ready to play
The FDA has issued warnings and recalled certain compounded versions of GLP-1 weight-loss drugs due to safety concerns, including contamination and manufacturing violations. Despite restrictions, some consumers continue to purchase lower-cost knockoff drugs through telehealth and medical spas. The FDA highlights risks associated with unapproved compounded medications, emphasizing that FDA-approved drugs are tested for safety and efficacy.
Notice: This Is an AI-Generated Summary
Comments (0)